Omalizumab for the treatment of chronic spontaneous urticaria in daily clinical practice in South Spain

Dermatol Ther. 2018 Sep;31(5):e12669. doi: 10.1111/dth.12669. Epub 2018 Jul 31.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Allergic Agents / therapeutic use*
  • Chronic Disease
  • Female
  • Humans
  • Male
  • Omalizumab / therapeutic use*
  • Quality of Life
  • Severity of Illness Index
  • Spain
  • Urticaria / drug therapy*

Substances

  • Anti-Allergic Agents
  • Omalizumab